Comparison 4. Budesonide 6 mg vs 3 mg.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Maintenance of Clinical Remissions	3		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
1.1 3 months	3	180	Risk Ratio (M‐H, Random, 95% CI)	1.07 [0.85, 1.34]
1.2 6 months	3	180	Risk Ratio (M‐H, Random, 95% CI)	1.12 [0.85, 1.47]
1.3 12 months	3	180	Risk Ratio (M‐H, Random, 95% CI)	1.18 [0.85, 1.65]
2 Change in CDAI from baseline	3		Mean Difference (IV, Random, 95% CI)	Subtotals only
2.1 3 months	3	180	Mean Difference (IV, Random, 95% CI)	‐15.11 [‐41.10, 10.88]
2.2 6 months	3	180	Mean Difference (IV, Random, 95% CI)	‐27.44 [‐52.09, ‐2.79]
2.3 12 months	3	180	Mean Difference (IV, Random, 95% CI)	‐26.42 [‐69.55, 16.70]
3 Mean Time to Relapse (days)	3	117	Mean Difference (IV, Random, 95% CI)	29.67 [‐4.83, 64.18]
4 Withdrawals Due to Treatment Failure	3	180	Risk Ratio (M‐H, Random, 95% CI)	0.89 [0.68, 1.16]
5 Proportion of Patients with Treatment‐Related Adverse Events at 12 months	3	179	Risk Ratio (M‐H, Random, 95% CI)	1.18 [0.60, 2.32]
6 Withdrawals Due to Adverse Events	2	111	Risk Ratio (M‐H, Random, 95% CI)	1.18 [0.08, 17.82]
7 Abnormal ACTH Stimulation Test	3	167	Risk Ratio (M‐H, Random, 95% CI)	1.49 [1.00, 2.24]